ID   DDR1_HUMAN              Reviewed;         913 AA.
AC   Q08345; B5A975; B5A976; B7Z2K0; Q14196; Q16562; Q2L6H3; Q4LE50; Q5ST11;
AC   Q5ST12; Q6NSK4; Q9UD35; Q9UD36; Q9UD37; Q9UD86; Q9UDL2;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   12-OCT-2022, entry version 230.
DE   RecName: Full=Epithelial discoidin domain-containing receptor 1;
DE            Short=Epithelial discoidin domain receptor 1;
DE            EC=2.7.10.1;
DE   AltName: Full=CD167 antigen-like family member A;
DE   AltName: Full=Cell adhesion kinase;
DE   AltName: Full=Discoidin receptor tyrosine kinase;
DE   AltName: Full=HGK2;
DE   AltName: Full=Mammary carcinoma kinase 10;
DE            Short=MCK-10;
DE   AltName: Full=Protein-tyrosine kinase 3A;
DE   AltName: Full=Protein-tyrosine kinase RTK-6;
DE   AltName: Full=TRK E;
DE   AltName: Full=Tyrosine kinase DDR;
DE   AltName: Full=Tyrosine-protein kinase CAK;
DE   AltName: CD_antigen=CD167a;
DE   Flags: Precursor;
GN   Name=DDR1; Synonyms=CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Keratinocyte;
RX   PubMed=8226977; DOI=10.1016/s0021-9258(20)80524-9;
RA   di Marco E., Cutuli N., Guerra L., Cancedda R., de Luca M.;
RT   "Molecular cloning of trkE, a novel trk-related putative tyrosine kinase
RT   receptor isolated from normal human keratinocytes and widely expressed by
RT   normal human tissues.";
RL   J. Biol. Chem. 268:24290-24295(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-833.
RC   TISSUE=Placenta;
RX   PubMed=8390675; DOI=10.1073/pnas.90.12.5677;
RA   Johnson J.D., Edman J.C., Rutter W.J.;
RT   "A receptor tyrosine kinase found in breast carcinoma cells has an
RT   extracellular discoidin I-like domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5677-5681(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Ovary;
RX   PubMed=7848919;
RA   Laval S., Butler R., Shelling A.N., Hanby A.M., Poulsom R., Ganesan T.S.;
RT   "Isolation and characterization of an epithelial-specific receptor tyrosine
RT   kinase from an ovarian cancer cell line.";
RL   Cell Growth Differ. 5:1173-1183(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RX   PubMed=8302582;
RA   Perez J.L., Shen X., Finkernagel S., Sciorra L., Jenkins N.A.,
RA   Gilbert D.J., Copeland N.G., Wong T.W.;
RT   "Identification and chromosomal mapping of a receptor tyrosine kinase with
RT   a putative phospholipid binding sequence in its ectodomain.";
RL   Oncogene 9:211-219(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-833.
RX   PubMed=8977099; DOI=10.1016/s0014-5793(96)01234-3;
RA   Sakuma S., Tada M., Saya H., Sawamura Y., Shinohe Y., Abe H.;
RT   "Receptor protein tyrosine kinase DDR is up-regulated by p53 protein.";
RL   FEBS Lett. 398:165-169(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8796349; DOI=10.1101/gr.6.7.620;
RA   Playford M.P., Butler R.J., Wang X.C., Katso R.M., Cooke I.E.,
RA   Ganesan T.S.;
RT   "The genomic structure of discoidin receptor tyrosine kinase.";
RL   Genome Res. 6:620-627(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=8622863;
RA   Perez J.L., Jing S.Q., Wong T.W.;
RT   "Identification of two isoforms of the Cak receptor kinase that are
RT   coexpressed in breast tumor cell lines.";
RL   Oncogene 12:1469-1477(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [MRNA] OF
RP   1-286 (ISOFORMS 1/2/4).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5).
RC   TISSUE=Brain, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R.,
RA   Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long cDNAs
RT   encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=16702430; DOI=10.1534/genetics.106.057034;
RA   Shiina T., Ota M., Shimizu S., Katsuyama Y., Hashimoto N., Takasu M.,
RA   Anzai T., Kulski J.K., Kikkawa E., Naruse T., Kimura N., Yanagiya K.,
RA   Watanabe A., Hosomichi K., Kohara S., Iwamoto C., Umehara Y., Meyer A.,
RA   Wanner V., Sano K., Macquin C., Ikeo K., Tokunaga K., Gojobori T.,
RA   Inoko H., Bahram S.;
RT   "Rapid evolution of major histocompatibility complex class I genes in
RT   primates generates new disease alleles in humans via hitchhiking
RT   diversity.";
RL   Genetics 173:1555-1570(2006).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PROTEIN SEQUENCE OF 480-490; 515-525 AND 790-798, IDENTIFICATION BY MASS
RP   SPECTROMETRY, SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-484;
RP   TYR-513; TYR-520; TYR-792; TYR-796 AND TYR-797, GLYCOSYLATION AT ASN-211
RP   AND ASN-260, AND MUTAGENESIS OF ARG-105; ASN-211; SER-213; ASN-260;
RP   ASN-371; THR-379; THR-393; ASN-394 AND LYS-655.
RX   PubMed=24509848; DOI=10.1074/jbc.m113.541102;
RA   Fu H.L., Valiathan R.R., Payne L., Kumarasiri M., Mahasenan K.V.,
RA   Mobashery S., Huang P., Fridman R.;
RT   "Glycosylation at Asn211 regulates the activation state of the discoidin
RT   domain receptor 1 (DDR1).";
RL   J. Biol. Chem. 289:9275-9287(2014).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 501-550 (ISOFORMS 1/4), NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 501-550 AND 651-694 (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   651-694 (ISOFORM 4), ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=7845687;
RA   Alves F., Vogel W., Mossie K., Millauer B., Hoefler H., Ullrich A.;
RT   "Distinct structural characteristics of discoidin I subfamily receptor
RT   tyrosine kinases and complementary expression in human cancer.";
RL   Oncogene 10:609-618(1995).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 771-824 (ISOFORMS 1/2/4).
RX   PubMed=7834423; DOI=10.1007/bf02303537;
RA   Weiner T.M., Liu E.T., Craven R.J., Cance W.G.;
RT   "Expression of growth factor receptors, the focal adhesion kinase, and
RT   other tyrosine kinases in human soft tissue tumors.";
RL   Ann. Surg. Oncol. 1:18-27(1994).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 772-823 (ISOFORMS 1/2/4), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [19]
RP   FUNCTION AS COLLAGEN RECEPTOR, PHOSPHORYLATION AT TYR-513, INTERACTION WITH
RP   SHC1, AUTOPHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9659899; DOI=10.1016/s1097-2765(00)80003-9;
RA   Vogel W., Gish G.D., Alves F., Pawson T.;
RT   "The discoidin domain receptor tyrosine kinases are activated by
RT   collagen.";
RL   Mol. Cell 1:13-23(1997).
RN   [20]
RP   FUNCTION.
RX   PubMed=12065315; DOI=10.1161/01.res.0000022166.74073.f8;
RA   Hou G., Vogel W.F., Bendeck M.P.;
RT   "Tyrosine kinase activity of discoidin domain receptor 1 is necessary for
RT   smooth muscle cell migration and matrix metalloproteinase expression.";
RL   Circ. Res. 90:1147-1149(2002).
RN   [21]
RP   FUNCTION, INTERACTION WITH PTPN11 AND NCK2, PHOSPHORYLATION AT TYR-740, AND
RP   MUTAGENESIS OF TYR-740.
RX   PubMed=16337946; DOI=10.1016/j.febslet.2005.11.035;
RA   Koo D.H., McFadden C., Huang Y., Abdulhussein R., Friese-Hamim M.,
RA   Vogel W.F.;
RT   "Pinpointing phosphotyrosine-dependent interactions downstream of the
RT   collagen receptor DDR1.";
RL   FEBS Lett. 580:15-22(2006).
RN   [22]
RP   FUNCTION.
RX   PubMed=16234985; DOI=10.1007/s11060-005-6874-1;
RA   Ram R., Lorente G., Nikolich K., Urfer R., Foehr E., Nagavarapu U.;
RT   "Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion and
RT   adhesion in association with matrix metalloproteinase-2.";
RL   J. Neurooncol. 76:239-248(2006).
RN   [23]
RP   INTERACTION WITH WWC1 AND PRKCZ.
RX   PubMed=18190796; DOI=10.1016/j.bbamcr.2007.12.007;
RA   Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W., Daly R.J.,
RA   Ormandy C.J.;
RT   "KIBRA interacts with discoidin domain receptor 1 to modulate collagen-
RT   induced signalling.";
RL   Biochim. Biophys. Acta 1783:383-393(2008).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION WITH
RP   MYH9.
RX   PubMed=19401332; DOI=10.1242/jcs.046219;
RA   Huang Y., Arora P., McCulloch C.A., Vogel W.F.;
RT   "The collagen receptor DDR1 regulates cell spreading and motility by
RT   associating with myosin IIA.";
RL   J. Cell Sci. 122:1637-1646(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH CDH1.
RX   PubMed=20432435; DOI=10.1002/jcp.22134;
RA   Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L., Hwang C.C.,
RA   Wang H.M., Wang C.Z.;
RT   "DDR1 regulates the stabilization of cell surface E-cadherin and E-
RT   cadherin-mediated cell aggregation.";
RL   J. Cell. Physiol. 224:387-397(2010).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH SRC.
RX   PubMed=20093046; DOI=10.1016/j.carpath.2009.12.006;
RA   Lu K.K., Trcka D., Bendeck M.P.;
RT   "Collagen stimulates discoidin domain receptor 1-mediated migration of
RT   smooth muscle cells through Src.";
RL   Cardiovasc. Pathol. 20:71-76(2011).
RN   [28]
RP   FUNCTION.
RX   PubMed=20884741; DOI=10.1183/09031936.00039710;
RA   Roberts M.E., Magowan L., Hall I.P., Johnson S.R.;
RT   "Discoidin domain receptor 1 regulates bronchial epithelial repair and
RT   matrix metalloproteinase production.";
RL   Eur. Respir. J. 37:1482-1493(2011).
RN   [29]
RP   FUNCTION AS COLLAGEN RECEPTOR, AND AUTOPHOSPHORYLATION.
RX   PubMed=21044884; DOI=10.1016/j.matbio.2010.10.004;
RA   Xu H., Raynal N., Stathopoulos S., Myllyharju J., Farndale R.W.,
RA   Leitinger B.;
RT   "Collagen binding specificity of the discoidin domain receptors: binding
RT   sites on collagens II and III and molecular determinants for collagen IV
RT   recognition by DDR1.";
RL   Matrix Biol. 30:16-26(2011).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 29-367 IN COMPLEX WITH INHIBITORY
RP   ANTIBODY, SUBUNIT, CALCIUM-BINDING SITES, GLYCOSYLATION AT ASN-211 AND
RP   ASN-260, AND DISULFIDE BONDS.
RX   PubMed=22483115; DOI=10.1016/j.str.2012.02.011;
RA   Carafoli F., Mayer M.C., Shiraishi K., Pecheva M.A., Chan L.Y., Nan R.,
RA   Leitinger B., Hohenester E.;
RT   "Structure of the discoidin domain receptor 1 extracellular region bound to
RT   an inhibitory Fab fragment reveals features important for signaling.";
RL   Structure 20:688-697(2012).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 601-913 IN COMPLEX WITH
RP   INHIBITOR, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF GLY-707.
RX   PubMed=23899692; DOI=10.1021/cb400430t;
RA   Kim H.G., Tan L., Weisberg E.L., Liu F., Canning P., Choi H.G., Ezell S.A.,
RA   Wu H., Zhao Z., Wang J., Mandinova A., Griffin J.D., Bullock A.N., Liu Q.,
RA   Lee S.W., Gray N.S.;
RT   "Discovery of a potent and selective DDR1 receptor tyrosine kinase
RT   inhibitor.";
RL   ACS Chem. Biol. 8:2145-2150(2013).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 601-913 IN COMPLEXES WITH
RP   INHIBITORS IMATINIB AND PONATINIB, ACTIVITY REGULATION, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=24768818; DOI=10.1016/j.jmb.2014.04.014;
RA   Canning P., Tan L., Chu K., Lee S.W., Gray N.S., Bullock A.N.;
RT   "Structural mechanisms determining inhibition of the collagen receptor DDR1
RT   by selective and multi-targeted type II kinase inhibitors.";
RL   J. Mol. Biol. 426:2457-2470(2014).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-17; ALA-100; GLN-169; ASP-170; TRP-306
RP   AND ALA-496.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine kinase that functions as cell surface receptor for
CC       fibrillar collagen and regulates cell attachment to the extracellular
CC       matrix, remodeling of the extracellular matrix, cell migration,
CC       differentiation, survival and cell proliferation. Collagen binding
CC       triggers a signaling pathway that involves SRC and leads to the
CC       activation of MAP kinases. Regulates remodeling of the extracellular
CC       matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and
CC       MMP9, and thereby facilitates cell migration and wound healing.
CC       Required for normal blastocyst implantation during pregnancy, for
CC       normal mammary gland differentiation and normal lactation. Required for
CC       normal ear morphology and normal hearing (By similarity). Promotes
CC       smooth muscle cell migration, and thereby contributes to arterial wound
CC       healing. Also plays a role in tumor cell invasion. Phosphorylates
CC       PTPN11. {ECO:0000250, ECO:0000269|PubMed:12065315,
CC       ECO:0000269|PubMed:16234985, ECO:0000269|PubMed:16337946,
CC       ECO:0000269|PubMed:19401332, ECO:0000269|PubMed:20093046,
CC       ECO:0000269|PubMed:20432435, ECO:0000269|PubMed:20884741,
CC       ECO:0000269|PubMed:21044884, ECO:0000269|PubMed:9659899}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- ACTIVITY REGULATION: Inhibited by the multi-targeted cancer drugs
CC       imatinib and ponatinib. {ECO:0000269|PubMed:24768818}.
CC   -!- SUBUNIT: Homodimer. Interacts (via PPxY motif) with WWC1 (via WW
CC       domains) in a collagen-regulated manner. Forms a tripartite complex
CC       with WWC1 and PRKCZ, but predominantly in the absence of collagen.
CC       Interacts (tyrosine phosphorylated) with SHC1. Interacts with SRC.
CC       Interacts with MYH9. Interacts with CDH1. Interacts with PTPN11.
CC       Interacts with NCK2. {ECO:0000269|PubMed:16337946,
CC       ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:19401332,
CC       ECO:0000269|PubMed:20093046, ECO:0000269|PubMed:20432435,
CC       ECO:0000269|PubMed:22483115, ECO:0000269|PubMed:23899692,
CC       ECO:0000269|PubMed:24509848, ECO:0000269|PubMed:9659899}.
CC   -!- INTERACTION:
CC       Q08345; Q16832: DDR2; NbExp=2; IntAct=EBI-711879, EBI-1381484;
CC       Q08345; O43639: NCK2; NbExp=3; IntAct=EBI-711879, EBI-713635;
CC       Q08345; Q06124: PTPN11; NbExp=4; IntAct=EBI-711879, EBI-297779;
CC       Q08345-2; Q9UHD9: UBQLN2; NbExp=5; IntAct=EBI-711903, EBI-947187;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=CAK I, DDR1b;
CC         IsoId=Q08345-1; Sequence=Displayed;
CC       Name=2; Synonyms=CAK II, DDR1a, Short;
CC         IsoId=Q08345-2; Sequence=VSP_002953;
CC       Name=3; Synonyms=DDR1d;
CC         IsoId=Q08345-4; Sequence=VSP_036916, VSP_036917;
CC       Name=4;
CC         IsoId=Q08345-5; Sequence=VSP_038057;
CC       Name=5;
CC         IsoId=Q08345-6; Sequence=VSP_043582, VSP_002953;
CC   -!- TISSUE SPECIFICITY: Detected in T-47D, MDA-MB-175 and HBL-100 breast
CC       carcinoma cells, A-431 epidermoid carcinoma cells, SW48 and SNU-C2B
CC       colon carcinoma cells and Hs 294T melanoma cells (at protein level).
CC       Expressed at low levels in most adult tissues and is highest in the
CC       brain, lung, placenta and kidney. Lower levels of expression are
CC       detected in melanocytes, heart, liver, skeletal muscle and pancreas.
CC       Abundant in breast carcinoma cell lines. In the colonic mucosa,
CC       expressed in epithelia but not in the connective tissue of the lamina
CC       propria. In the thyroid gland, expressed in the epithelium of the
CC       thyroid follicles. In pancreas, expressed in the islets of Langerhans
CC       cells, but not in the surrounding epithelial cells of the exocrine
CC       pancreas. In kidney, expressed in the epithelia of the distal tubules.
CC       Not expressed in connective tissue, endothelial cells, adipose tissue,
CC       muscle cells or cells of hematopoietic origin.
CC       {ECO:0000269|PubMed:7845687, ECO:0000269|PubMed:7848919,
CC       ECO:0000269|PubMed:8247543}.
CC   -!- DOMAIN: The Gly/Pro-rich domains may be required for an unusual
CC       geometry of interaction with ligand or substrates.
CC   -!- PTM: Autophosphorylated in response to fibrillar collagen binding.
CC   -!- PTM: Glycosylation of Asn-211, but apparently not of Asn-260 or Asn-
CC       394, prevents autophosphorylation from occurring in the absence of
CC       collagen. {ECO:0000269|PubMed:22483115, ECO:0000269|PubMed:24509848}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- CAUTION: The mutant Gln-371 studied is still likely to be glycosylated
CC       at Asn-370, but study did not include mutagenesis of Asn-370.
CC       {ECO:0000305|PubMed:24509848}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=ACF47649.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAE06103.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DDR1ID40280ch6p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X74979; CAA52915.1; -; mRNA.
DR   EMBL; L11315; AAA02866.1; -; mRNA.
DR   EMBL; Z29093; CAA82335.1; -; mRNA.
DR   EMBL; L20817; AAA18019.1; -; mRNA.
DR   EMBL; U48705; AAC50917.1; -; Genomic_DNA.
DR   EMBL; X98208; CAA66871.1; -; Genomic_DNA.
DR   EMBL; X99023; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99024; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99025; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99026; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99027; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99028; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99029; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99030; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99031; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99032; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99033; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99034; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; L57508; AAB05208.1; -; mRNA.
DR   EMBL; EU826613; ACF47649.1; ALT_SEQ; mRNA.
DR   EMBL; EU826614; ACF47650.1; -; mRNA.
DR   EMBL; AK291621; BAF84310.1; -; mRNA.
DR   EMBL; AK294793; BAH11886.1; -; mRNA.
DR   EMBL; AB210021; BAE06103.1; ALT_INIT; mRNA.
DR   EMBL; BA000025; BAB63318.1; -; Genomic_DNA.
DR   EMBL; CR759747; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB088102; BAC54935.1; -; Genomic_DNA.
DR   EMBL; AB103608; BAF31270.1; -; Genomic_DNA.
DR   EMBL; AL662854; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662870; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL773541; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL773589; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB202100; BAE78621.1; -; Genomic_DNA.
DR   EMBL; BX927194; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03335.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03338.1; -; Genomic_DNA.
DR   EMBL; BC008716; AAH08716.1; -; mRNA.
DR   EMBL; BC013400; AAH13400.1; -; mRNA.
DR   EMBL; BC070070; AAH70070.1; -; mRNA.
DR   CCDS; CCDS34385.1; -. [Q08345-1]
DR   CCDS; CCDS4690.1; -. [Q08345-2]
DR   CCDS; CCDS47396.1; -. [Q08345-5]
DR   CCDS; CCDS56411.1; -. [Q08345-2]
DR   PIR; A48280; A48280.
DR   PIR; A49508; A49508.
DR   RefSeq; NP_001189450.1; NM_001202521.1.
DR   RefSeq; NP_001189451.1; NM_001202522.1.
DR   RefSeq; NP_001189452.1; NM_001202523.1. [Q08345-2]
DR   RefSeq; NP_001284581.1; NM_001297652.1. [Q08345-2]
DR   RefSeq; NP_001284582.1; NM_001297653.1. [Q08345-2]
DR   RefSeq; NP_001284583.1; NM_001297654.1. [Q08345-1]
DR   RefSeq; NP_001945.3; NM_001954.4. [Q08345-2]
DR   RefSeq; NP_054699.2; NM_013993.2. [Q08345-1]
DR   RefSeq; NP_054700.2; NM_013994.2. [Q08345-5]
DR   PDB; 3ZOS; X-ray; 1.92 A; A/B=601-913.
DR   PDB; 4AG4; X-ray; 2.80 A; A=29-367.
DR   PDB; 4BKJ; X-ray; 1.70 A; A/B=601-913.
DR   PDB; 4CKR; X-ray; 2.20 A; A=601-913.
DR   PDB; 5BVK; X-ray; 2.29 A; A=595-913.
DR   PDB; 5BVN; X-ray; 2.21 A; A=595-913.
DR   PDB; 5BVO; X-ray; 1.98 A; A=595-913.
DR   PDB; 5BVW; X-ray; 1.94 A; A=595-913.
DR   PDB; 5FDP; X-ray; 2.25 A; A=601-913.
DR   PDB; 5FDX; X-ray; 2.65 A; A/B=601-913.
DR   PDB; 6BRJ; X-ray; 2.23 A; A=1-913.
DR   PDB; 6BSD; X-ray; 2.61 A; A=1-913.
DR   PDB; 6FEW; X-ray; 1.44 A; A=593-913.
DR   PDB; 6FEX; X-ray; 1.29 A; A=593-913.
DR   PDB; 6FIL; X-ray; 1.73 A; A=593-913.
DR   PDB; 6FIN; X-ray; 1.67 A; A=593-913.
DR   PDB; 6FIO; X-ray; 1.99 A; A=593-913.
DR   PDB; 6FIQ; X-ray; 1.79 A; A=593-913.
DR   PDB; 6GWR; X-ray; 2.07 A; A/B=601-913.
DR   PDB; 6HP9; X-ray; 1.96 A; A/B=601-913.
DR   PDB; 6Y23; X-ray; 2.58 A; A/B/C=566-913.
DR   PDB; 7BCM; X-ray; 2.30 A; A/B=601-913.
DR   PDB; 7BE6; X-ray; 1.87 A; A=601-913.
DR   PDBsum; 3ZOS; -.
DR   PDBsum; 4AG4; -.
DR   PDBsum; 4BKJ; -.
DR   PDBsum; 4CKR; -.
DR   PDBsum; 5BVK; -.
DR   PDBsum; 5BVN; -.
DR   PDBsum; 5BVO; -.
DR   PDBsum; 5BVW; -.
DR   PDBsum; 5FDP; -.
DR   PDBsum; 5FDX; -.
DR   PDBsum; 6BRJ; -.
DR   PDBsum; 6BSD; -.
DR   PDBsum; 6FEW; -.
DR   PDBsum; 6FEX; -.
DR   PDBsum; 6FIL; -.
DR   PDBsum; 6FIN; -.
DR   PDBsum; 6FIO; -.
DR   PDBsum; 6FIQ; -.
DR   PDBsum; 6GWR; -.
DR   PDBsum; 6HP9; -.
DR   PDBsum; 6Y23; -.
DR   PDBsum; 7BCM; -.
DR   PDBsum; 7BE6; -.
DR   AlphaFoldDB; Q08345; -.
DR   SMR; Q08345; -.
DR   BioGRID; 107234; 126.
DR   CORUM; Q08345; -.
DR   DIP; DIP-39698N; -.
DR   IntAct; Q08345; 95.
DR   MINT; Q08345; -.
DR   STRING; 9606.ENSP00000427552; -.
DR   BindingDB; Q08345; -.
DR   ChEMBL; CHEMBL5319; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB15822; Pralsetinib.
DR   DrugCentral; Q08345; -.
DR   GuidetoPHARMACOLOGY; 1843; -.
DR   GlyGen; Q08345; 5 sites.
DR   iPTMnet; Q08345; -.
DR   PhosphoSitePlus; Q08345; -.
DR   BioMuta; DDR1; -.
DR   DMDM; 729008; -.
DR   EPD; Q08345; -.
DR   jPOST; Q08345; -.
DR   MassIVE; Q08345; -.
DR   MaxQB; Q08345; -.
DR   PaxDb; Q08345; -.
DR   PeptideAtlas; Q08345; -.
DR   PRIDE; Q08345; -.
DR   ProteomicsDB; 58595; -. [Q08345-1]
DR   ProteomicsDB; 58596; -. [Q08345-2]
DR   ProteomicsDB; 58597; -. [Q08345-4]
DR   ProteomicsDB; 58598; -. [Q08345-5]
DR   ProteomicsDB; 58599; -. [Q08345-6]
DR   ABCD; Q08345; 1 sequenced antibody.
DR   Antibodypedia; 48090; 838 antibodies from 42 providers.
DR   DNASU; 780; -.
DR   Ensembl; ENST00000259875.11; ENSP00000259875.7; ENSG00000137332.19. [Q08345-2]
DR   Ensembl; ENST00000324771.12; ENSP00000318217.8; ENSG00000204580.14. [Q08345-1]
DR   Ensembl; ENST00000376567.6; ENSP00000365751.2; ENSG00000204580.14. [Q08345-2]
DR   Ensembl; ENST00000376568.8; ENSP00000365752.3; ENSG00000204580.14. [Q08345-1]
DR   Ensembl; ENST00000376569.7; ENSP00000365753.3; ENSG00000204580.14. [Q08345-2]
DR   Ensembl; ENST00000376570.8; ENSP00000365754.4; ENSG00000204580.14. [Q08345-2]
DR   Ensembl; ENST00000376575.7; ENSP00000365759.4; ENSG00000204580.14. [Q08345-4]
DR   Ensembl; ENST00000383377.6; ENSP00000372868.2; ENSG00000137332.19. [Q08345-1]
DR   Ensembl; ENST00000400410.5; ENSP00000383261.1; ENSG00000137332.19. [Q08345-2]
DR   Ensembl; ENST00000400411.5; ENSP00000383262.1; ENSG00000137332.19. [Q08345-2]
DR   Ensembl; ENST00000400414.5; ENSP00000383265.1; ENSG00000137332.19. [Q08345-1]
DR   Ensembl; ENST00000400486.5; ENSP00000383334.1; ENSG00000215522.11. [Q08345-2]
DR   Ensembl; ENST00000400488.5; ENSP00000383336.1; ENSG00000215522.11. [Q08345-2]
DR   Ensembl; ENST00000400489.7; ENSP00000383337.3; ENSG00000215522.11. [Q08345-2]
DR   Ensembl; ENST00000400491.5; ENSP00000383338.1; ENSG00000215522.11. [Q08345-1]
DR   Ensembl; ENST00000400492.5; ENSP00000383339.1; ENSG00000215522.11. [Q08345-1]
DR   Ensembl; ENST00000412329.5; ENSP00000391805.1; ENSG00000230456.10. [Q08345-1]
DR   Ensembl; ENST00000415092.5; ENSP00000405540.1; ENSG00000230456.10. [Q08345-2]
DR   Ensembl; ENST00000418800.6; ENSP00000407699.2; ENSG00000204580.14. [Q08345-2]
DR   Ensembl; ENST00000419412.5; ENSP00000416183.1; ENSG00000234078.10. [Q08345-2]
DR   Ensembl; ENST00000421229.6; ENSP00000415730.2; ENSG00000234078.10. [Q08345-2]
DR   Ensembl; ENST00000427053.6; ENSP00000416145.2; ENSG00000230456.10. [Q08345-2]
DR   Ensembl; ENST00000429699.5; ENSP00000401397.1; ENSG00000234078.10. [Q08345-1]
DR   Ensembl; ENST00000430933.5; ENSP00000397769.1; ENSG00000234078.10. [Q08345-1]
DR   Ensembl; ENST00000449518.5; ENSP00000414285.1; ENSG00000230456.10. [Q08345-1]
DR   Ensembl; ENST00000452441.5; ENSP00000405039.1; ENSG00000204580.14. [Q08345-1]
DR   Ensembl; ENST00000453510.5; ENSP00000401208.1; ENSG00000230456.10. [Q08345-2]
DR   Ensembl; ENST00000454612.6; ENSP00000406091.2; ENSG00000204580.14. [Q08345-2]
DR   Ensembl; ENST00000454774.5; ENSP00000400393.1; ENSG00000234078.10. [Q08345-2]
DR   Ensembl; ENST00000482873.6; ENSP00000421978.1; ENSG00000204580.14. [Q08345-4]
DR   Ensembl; ENST00000508312.5; ENSP00000422442.1; ENSG00000204580.14. [Q08345-6]
DR   Ensembl; ENST00000513240.5; ENSP00000427552.1; ENSG00000204580.14. [Q08345-5]
DR   Ensembl; ENST00000548133.4; ENSP00000449611.2; ENSG00000230456.10. [Q08345-1]
DR   Ensembl; ENST00000548962.5; ENSP00000448115.2; ENSG00000230456.10. [Q08345-6]
DR   Ensembl; ENST00000549026.3; ENSP00000449238.2; ENSG00000215522.11. [Q08345-6]
DR   Ensembl; ENST00000550384.5; ENSP00000447474.2; ENSG00000234078.10. [Q08345-6]
DR   Ensembl; ENST00000550395.5; ENSP00000449255.2; ENSG00000215522.11. [Q08345-1]
DR   Ensembl; ENST00000552068.5; ENSP00000449190.2; ENSG00000234078.10. [Q08345-1]
DR   Ensembl; ENST00000552721.4; ENSP00000449307.2; ENSG00000137332.19. [Q08345-6]
DR   Ensembl; ENST00000553015.5; ENSP00000448377.2; ENSG00000137332.19. [Q08345-1]
DR   Ensembl; ENST00000617572.3; ENSP00000479195.1; ENSG00000215522.11. [Q08345-4]
DR   Ensembl; ENST00000618059.2; ENSP00000479204.1; ENSG00000234078.10. [Q08345-4]
DR   Ensembl; ENST00000620318.4; ENSP00000484588.1; ENSG00000137332.19. [Q08345-4]
DR   Ensembl; ENST00000621544.4; ENSP00000484013.1; ENSG00000230456.10. [Q08345-4]
DR   GeneID; 780; -.
DR   KEGG; hsa:780; -.
DR   MANE-Select; ENST00000376568.8; ENSP00000365752.3; NM_001297654.2; NP_001284583.1.
DR   UCSC; uc003nrq.4; human. [Q08345-1]
DR   CTD; 780; -.
DR   DisGeNET; 780; -.
DR   GeneCards; DDR1; -.
DR   HGNC; HGNC:2730; DDR1.
DR   HPA; ENSG00000204580; Low tissue specificity.
DR   MIM; 600408; gene.
DR   neXtProt; NX_Q08345; -.
DR   OpenTargets; ENSG00000204580; -.
DR   PharmGKB; PA24348; -.
DR   VEuPathDB; HostDB:ENSG00000204580; -.
DR   eggNOG; KOG1094; Eukaryota.
DR   GeneTree; ENSGT00940000159733; -.
DR   HOGENOM; CLU_008873_2_0_1; -.
DR   InParanoid; Q08345; -.
DR   OMA; QILRCHF; -.
DR   OrthoDB; 227725at2759; -.
DR   PhylomeDB; Q08345; -.
DR   TreeFam; TF317840; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q08345; -.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   SignaLink; Q08345; -.
DR   SIGNOR; Q08345; -.
DR   BioGRID-ORCS; 780; 17 hits in 1113 CRISPR screens.
DR   ChiTaRS; DDR1; human.
DR   GeneWiki; DDR1; -.
DR   GenomeRNAi; 780; -.
DR   Pharos; Q08345; Tchem.
DR   PRO; PR:Q08345; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q08345; protein.
DR   Bgee; ENSG00000137332; Expressed in cerebral cortex and 4 other tissues.
DR   ExpressionAtlas; Q08345; baseline and differential.
DR   Genevisible; Q08345; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0038062; F:protein tyrosine kinase collagen receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0061564; P:axon development; IEA:Ensembl.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0038063; P:collagen-activated tyrosine kinase receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043583; P:ear development; IEA:Ensembl.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0007595; P:lactation; IEA:UniProtKB-KW.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:1990138; P:neuron projection extension; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0001952; P:regulation of cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB.
DR   GO; GO:0014909; P:smooth muscle cell migration; IMP:UniProtKB.
DR   GO; GO:0061302; P:smooth muscle cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0044319; P:wound healing, spreading of cells; IMP:UniProtKB.
DR   CDD; cd00057; FA58C; 1.
DR   InterPro; IPR034299; DDR1/DDR2.
DR   InterPro; IPR000421; FA58C.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF295; PTHR24416:SF295; 1.
DR   Pfam; PF00754; F5_F8_type_C; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00231; FA58C; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01285; FA58C_1; 1.
DR   PROSITE; PS01286; FA58C_2; 1.
DR   PROSITE; PS50022; FA58C_3; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calcium; Cell membrane;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Kinase; Lactation;
KW   Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; Pregnancy;
KW   Receptor; Reference proteome; Secreted; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..913
FT                   /note="Epithelial discoidin domain-containing receptor 1"
FT                   /id="PRO_0000016742"
FT   TOPO_DOM        21..417
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        418..438
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        439..913
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          31..185
FT                   /note="F5/8 type C"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00081"
FT   DOMAIN          610..905
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          192..367
FT                   /note="DS-like domain"
FT   REGION          470..499
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           481..484
FT                   /note="PPxY motif"
FT   COMPBIAS        476..496
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        766
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         211
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT   BINDING         230
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT   BINDING         230
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT   BINDING         233
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT   BINDING         235
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT   BINDING         253
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT   BINDING         255
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT   BINDING         360
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT   BINDING         361
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT   BINDING         616..624
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         655
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         484
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MOD_RES         513
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:24509848,
FT                   ECO:0000269|PubMed:9659899"
FT   MOD_RES         520
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MOD_RES         631
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         740
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:16337946"
FT   MOD_RES         792
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MOD_RES         796
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MOD_RES         797
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   CARBOHYD        211
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22483115,
FT                   ECO:0000269|PubMed:24509848"
FT   CARBOHYD        260
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22483115,
FT                   ECO:0000269|PubMed:24509848"
FT   CARBOHYD        370
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        394
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        31..185
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00081,
FT                   ECO:0000269|PubMed:22483115"
FT   DISULFID        74..177
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00081,
FT                   ECO:0000269|PubMed:22483115"
FT   DISULFID        303..348
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00081,
FT                   ECO:0000269|PubMed:22483115"
FT   VAR_SEQ         1
FT                   /note="M -> MSLPRCCPHPLRPEGSGAM (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043582"
FT   VAR_SEQ         190..243
FT                   /note="GLLSYTAPVGQTMYLSEAVYLNDSTYDGHTVGGLQYGGLGQLADGVVGLDDF
FT                   RK -> CSMGVWASWQMVWWGWMTLGRVRSCGSGQAMTMWDGATTASPVAMWRWSLSLT
FT                   G (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_036916"
FT   VAR_SEQ         244..913
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_036917"
FT   VAR_SEQ         506..542
FT                   /note="Missing (in isoform 2 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:7845687,
FT                   ECO:0000303|PubMed:7848919, ECO:0000303|PubMed:8226977,
FT                   ECO:0000303|PubMed:8622863, ECO:0000303|Ref.10"
FT                   /id="VSP_002953"
FT   VAR_SEQ         665
FT                   /note="A -> ASFSLFS (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:7845687"
FT                   /id="VSP_038057"
FT   VARIANT         17
FT                   /note="S -> G (in dbSNP:rs55901302)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041492"
FT   VARIANT         100
FT                   /note="V -> A (in dbSNP:rs34544756)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041493"
FT   VARIANT         169
FT                   /note="R -> Q (in dbSNP:rs55980643)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041494"
FT   VARIANT         170
FT                   /note="A -> D (in dbSNP:rs56231803)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041495"
FT   VARIANT         306
FT                   /note="R -> W (in dbSNP:rs56024191)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041496"
FT   VARIANT         496
FT                   /note="S -> A (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041497"
FT   VARIANT         833
FT                   /note="L -> V (in dbSNP:rs2524235)"
FT                   /evidence="ECO:0000269|PubMed:8390675,
FT                   ECO:0000269|PubMed:8977099"
FT                   /id="VAR_049716"
FT   MUTAGEN         105
FT                   /note="R->A: Inhibits collagen-induced phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         211
FT                   /note="N->A: Phosphorylates regardless of collagen
FT                   presence, collagen addition does not alter significantly
FT                   the levels of constitutive phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         211
FT                   /note="N->Q: Sustained phosphorylation regardless of
FT                   collagen presence, collagen addition does not alter
FT                   significantly the levels of constitutive phosphorylation.
FT                   Located intracellularly and at the cell surface. Displays a
FT                   reduced rate of receptor internalization, which is not
FT                   altered in the presence of collagen. Able to bind collagen
FT                   as wild-type. Exhibits enhanced collagen-independent
FT                   receptor dimerization. Complete loss of the
FT                   collagen-independent constitutive activation; when
FT                   associated with A-655."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         213
FT                   /note="S->A: Phosphorylates regardless of collagen
FT                   presence, collagen addition does not alter significantly
FT                   the levels of constitutive phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         260
FT                   /note="N->Q: Phosphorylates in response to collagen, but at
FT                   lower levels compared to wild-type. No activation in the
FT                   absence of collagen."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         371
FT                   /note="N->Q: Phosphorylates in response to collagen, but at
FT                   lower levels compared to wild-type. No activation in the
FT                   absence of collagen."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         379
FT                   /note="T->A: Phosphorylates in response to collagen, but at
FT                   lower levels compared to wild-type. Phosphorylates in
FT                   response to collagen, but at lower levels compared to
FT                   wild-type; when associated with A-393."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         393
FT                   /note="T->A: Phosphorylates in response to collagen, but at
FT                   lower levels compared to wild-type. Phosphorylates in
FT                   response to collagen, but at lower levels compared to
FT                   wild-type; when associated with A-379."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         394
FT                   /note="N->Q: Phosphorylates in response to collagen, but at
FT                   lower levels compared to wild-type. No activation in the
FT                   absence of collagen."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         655
FT                   /note="K->A: Loss of kinase activity. Complete loss of the
FT                   collagen-independent constitutive activation; when
FT                   associated with Q-211."
FT                   /evidence="ECO:0000269|PubMed:24509848"
FT   MUTAGEN         707
FT                   /note="G->A: Confers over 20-fold resistance to the ability
FT                   of an inhibitor to inhibit autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:23899692"
FT   MUTAGEN         740
FT                   /note="Y->F: Abolishes interaction with PTPN11."
FT                   /evidence="ECO:0000269|PubMed:16337946"
FT   CONFLICT        94
FT                   /note="L -> V (in Ref. 2; AAA02866 and 5; AAC50917)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        165
FT                   /note="R -> H (in Ref. 14; AAH70070)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        285..286
FT                   /note="VH -> MW (in Ref. 8; ACF47649)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        741
FT                   /note="P -> Q (in Ref. 14; AAH70070)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        847..867
FT                   /note="QLTDEQVIENAGEFFRDQGRQ -> SAHRRAGHRERGGVLPGPGPA (in
FT                   Ref. 6; CAA66871)"
FT                   /evidence="ECO:0000305"
FT   TURN            37..39
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   HELIX           44..46
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          47..50
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   HELIX           55..57
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   HELIX           59..61
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   TURN            68..70
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          71..73
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          87..103
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   HELIX           107..109
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          116..127
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          129..131
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          145..148
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          151..169
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          178..186
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          191..197
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          217..220
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          223..226
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   HELIX           230..232
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          245..248
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   TURN            251..254
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          256..259
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   HELIX           260..262
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          266..287
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   HELIX           291..293
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          299..306
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          308..312
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          314..316
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          318..321
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          332..351
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          353..367
FT                   /evidence="ECO:0007829|PDB:4AG4"
FT   STRAND          582..584
FT                   /evidence="ECO:0007829|PDB:6Y23"
FT   HELIX           607..609
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          610..618
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          620..631
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           632..634
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          637..639
FT                   /evidence="ECO:0007829|PDB:4BKJ"
FT   STRAND          646..648
FT                   /evidence="ECO:0007829|PDB:7BE6"
FT   STRAND          651..657
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           663..676
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          687..691
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          693..696
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          698..702
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           709..714
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          717..720
FT                   /evidence="ECO:0007829|PDB:6FIO"
FT   STRAND          736..738
FT                   /evidence="ECO:0007829|PDB:6FIL"
FT   HELIX           740..759
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           769..771
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          772..774
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           776..778
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          780..782
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           786..788
FT                   /evidence="ECO:0007829|PDB:6Y23"
FT   HELIX           790..795
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   STRAND          796..799
FT                   /evidence="ECO:0007829|PDB:6FIQ"
FT   STRAND          802..805
FT                   /evidence="ECO:0007829|PDB:6FIQ"
FT   HELIX           807..809
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           812..817
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           822..837
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   TURN            838..840
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   TURN            844..847
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           850..862
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           878..887
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           892..894
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           898..907
FT                   /evidence="ECO:0007829|PDB:6FEX"
FT   HELIX           910..912
FT                   /evidence="ECO:0007829|PDB:4BKJ"
SQ   SEQUENCE   913 AA;  101128 MW;  C96913EA906C481E CRC64;
     MGPEALSSLL LLLLVASGDA DMKGHFDPAK CRYALGMQDR TIPDSDISAS SSWSDSTAAR
     HSRLESSDGD GAWCPAGSVF PKEEEYLQVD LQRLHLVALV GTQGRHAGGL GKEFSRSYRL
     RYSRDGRRWM GWKDRWGQEV ISGNEDPEGV VLKDLGPPMV ARLVRFYPRA DRVMSVCLRV
     ELYGCLWRDG LLSYTAPVGQ TMYLSEAVYL NDSTYDGHTV GGLQYGGLGQ LADGVVGLDD
     FRKSQELRVW PGYDYVGWSN HSFSSGYVEM EFEFDRLRAF QAMQVHCNNM HTLGARLPGG
     VECRFRRGPA MAWEGEPMRH NLGGNLGDPR ARAVSVPLGG RVARFLQCRF LFAGPWLLFS
     EISFISDVVN NSSPALGGTF PPAPWWPPGP PPTNFSSLEL EPRGQQPVAK AEGSPTAILI
     GCLVAIILLL LLIIALMLWR LHWRRLLSKA ERRVLEEELT VHLSVPGDTI LINNRPGPRE
     PPPYQEPRPR GNPPHSAPCV PNGSALLLSN PAYRLLLATY ARPPRGPGPP TPAWAKPTNT
     QAYSGDYMEP EKPGAPLLPP PPQNSVPHYA EADIVTLQGV TGGNTYAVPA LPPGAVGDGP
     PRVDFPRSRL RFKEKLGEGQ FGEVHLCEVD SPQDLVSLDF PLNVRKGHPL LVAVKILRPD
     ATKNARNDFL KEVKIMSRLK DPNIIRLLGV CVQDDPLCMI TDYMENGDLN QFLSAHQLED
     KAAEGAPGDG QAAQGPTISY PMLLHVAAQI ASGMRYLATL NFVHRDLATR NCLVGENFTI
     KIADFGMSRN LYAGDYYRVQ GRAVLPIRWM AWECILMGKF TTASDVWAFG VTLWEVLMLC
     RAQPFGQLTD EQVIENAGEF FRDQGRQVYL SRPPACPQGL YELMLRCWSR ESEQRPPFSQ
     LHRFLAEDAL NTV
//
